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Abstract
Introduction: Anaemia is prevalent among children born to HIV-positive women, and it is associated with adverse effects on
cognitive and motor development, growth, and increased risks of morbidity and mortality.
Objective: To examine the effect of daily multivitamin supplementation on haematologic status and mother-to-child
transmission (MTCT) of HIV through breastfeeding.
Methods: A total of 2387 infants born to HIV-positive women from Dar es Salaam, Tanzania were enrolled in a randomized,
double-blind, placebo-controlled trial, and provided a daily oral supplement of multivitamins (vitamin B complex, C and E) or
placebo at age 6 weeks for 24 months. Among them, 2008 infants provided blood samples and had haemoglobin concentrations
measured at baseline and during a follow-up period. Anaemia was defined as haemoglobin concentrationsB11 g/dL and severe
anaemiaB8.5 g/dL.
Results: Haemoglobin concentrations among children in the treatment group were significantly higher than those in the placebo
group at 12 (9.77 vs. 9.64 g/dL, p0.03), 18 (9.76 vs. 9.57 g/dL, p0.004), and 24 months (9.93 vs. 9.75 g/dL, p0.02) of
follow-up. Compared to those in the placebo group, children in the treatment group had a 12% lower risk of anaemia (hazard
ratio (HR): 0.88; 95% CI: 0.790.99; p0.03). The treatment was associated with a 28% reduced risk of severe anaemia among
children born to women without anaemia (HR: 0.72; 95% CI: 0.560.92; p0.008), but not among those born to women with
anaemia (HR: 1.10; 95% CI: 0.791.54; p0.57; p for interaction0.007). One thousand seven hundred fifty three infants
who tested HIV-negative at baseline and had HIV testing during follow-up were included in the analysis for MTCT of HIV.
No association was found between multivitamin supplements and MTCT of HIV.
Conclusions: Multivitamin supplements improve haematologic status among children born to HIV-positive women. Further trials
focusing on anaemia among HIV-exposed children are warranted in the context of antiretroviral therapy.
Keywords: multivitamins; haemoglobin; anaemia; mother-to-child transmission; randomized controlled trial; Tanzania.
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Introduction
Anaemia is the most prevalent nutrition-related public health
problem worldwide, particularly among infants and young
children in resource-limited settings. Infants born to HIV-
positive mothers are at higher risk for anaemia due to the
direct effect of HIV on erythropoiesis [1], exposure to anti-
retroviral therapy (ART) [2], HIV-associated infections [3], and
micronutrient deficiencies [4]. Many studies have demon-
strated that supplementation of multiple micronutrients is
effective to prevent or treat anaemia among young children
in resource-limited countries [59]. However, to our knowl-
edge, few studies have examined the effect of supplementa-
tion of micronutrients among HIV-positive or HIV-exposed
children [10].
We previously observed that multiple micronutrients
(B vitamins, vitamin C and vitamin E) were effective in reduc-
ing HIV progression among HIV-positive women, and the
supplementation decreased the risk of mother-to-child trans-
mission (MTCT)among immunologicallyandnutritionallycom-
promised HIV-positive women through breastfeeding [11,12].
To evaluate the efficacy of direct child supplementation on
MTCT and child anaemia status, we therefore conducted a
randomized trial of multivitamin supplementation (thiamine,
riboflavin, niacin, vitamin B6, folate, vitamin B12, vitamin C
and vitamin E) among infants born to HIV-positive women
living in Dar es Salaam, Tanzania. We aimed to examine the
effect of daily multivitamin supplementation on the child’s
haematologic status and MTCTof HIV through breastfeeding.
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Study participants
From February 2004 to June 2007, pregnant women aged
18 years or older presenting for prenatal care at the 32nd
week of gestation or earlier in one of the eight clinics in Dar
es Salaam, were offered HIVscreening with pre- and post-test
counselling. HIV-positive women were followed up to enrol
their infants into the randomized clinical trial. Infant
eligibility criteria included born to HIV-positive women,
singleton birth, age 57 weeks, and the mother intending
to reside in Dar es Salaam for at least two years after
delivery.We excluded from the study twin infants and infants
with multiple or serious congenital anomalies (such as
cyanotic congenital heart disease, spinal bifida) or other
medical conditions that would interfere with their ability to
comply with the study procedures. Eligible singleton birth
infants were randomly assigned to receive a daily oral dose
of multivitamins or placebo at age of six weeks (baseline) for
24 months. A randomization list from 1 to 2400 was prepared
according to a computer-generated sequence in a block of
20. The randomization list was provided to the pharmacy
department, with each a number corresponding to a code
denoting one of the two treatments. Infants enrolled at the
study clinic were provided the next consecutive number in
the series when they received the supply of daily regimen
from the pharmacist.
From age six weeks to six months, children in the multi-
vitamin treatment group received one capsule containing
60-mg vitamin C, 8-mg vitamin E, 0.5-mg thiamine, 0.6-mg
riboflavin, 4-mg niacin, 0.6 mg vitamin B6, 130-mg folate and
1-mg vitamin B12. For children older than six months, two
capsules were administered daily. These doses represent
150600% and 200400% of US adequate intake for children
aged 06 and 712 months, respectively, and 133800% of
the US Recommended Dietary Allowance (RDA) for children
aged 13 years. For these nutrients, tolerable upper intake
levels have not been defined for childrenB12 months; the
tolerable upper intake levels (if defined) were not exceeded
for children]12 months [1315].We did not include vitamin
A in our treatment regimen because vitamin A supplementa-
tion was associated with increased risk of MTCT through
breastfeeding [11,16]. In addition, all children in this study
received periodic large doses of vitamin A supplements
(100,000 IU at nine months and 200,000 IU at 15 and
21 months) as per Tanzania Ministry of Health guidelines.The
multivitamin supplement used was powder encapsulated in
an opaque gelatinous capsule, which was manufactured by
Nutriset (Malaunay, France). Mothers were instructed on
how to push the capsule through the back of the blister pack,
open it, and decant the powder into a small plastic cup.
Sterile water (5 mL) supplied with the supplement was added
to the powder, and the dose was given to the infants orally.
A pilot phase of open-label vitamin use in 12 infants and
mothers confirmed that this supplement preparation and use
was well-accepted by the mothers and infants. Both the
placebo and active capsules contained an orange tasting
powder that allowed for identical taste and appearance.
All study personnel and participants were blinded to
treatment assignment for the duration of the study. Only
the study statisticians and the data-monitoring committee
saw unblinded data, but none had any contact with study
participants.
Mothers and their children were asked to return to the
clinic every month for research visits and standard clinical
care. Mothers were counselled on the risks and benefits of
exclusive breastfeeding in keeping with WHO recommenda-
tions in place during the study period. At each clinic visit,
women were asked about infant feeding in the past seven
days. Information on the infant feeding during the first week
of life was requested at the first post-partum visit. During
monthly follow-up, infant-feeding practices (breastfeeding
status and frequency, introduction of other liquid or foods
including water, tea, juice, cow’s milk, infant formula, por-
ridge, mashed vegetable, meats, rice) was collected. We
defined exclusive breastfeeding as feeding a child with breast
milk only without additional foods. The duration of exclusive
breastfeeding was calculated as the mean of infant ages at
which the last time the mother reported that the child was
still exclusively breastfeeding and the first time the mother
reported that the child was given other foods in addition
to breast milk. Compliance with the daily regimen was
measured by pill counting by research nurses of unused
regimen.
When the study began in 2004, routine medical care
proposed for pregnant women with HIV infection included
malaria prophylaxis, diagnosis and treatment for sexually
transmitted diseases and prophylaxis, diagnosis and treat-
ment of opportunistic infections, and iron and folate sup-
plements during pregnancy. One dose of nevirapine was
given to the mother at the onset of labour and another dose
given to the infant within 72 hours of birth for the purpose of
prevention of MTCT [17]. As the study progressed, beginning
in July 2005, the availability of antiretroviral drugs increased
substantially through programmes including the President’s
Plan for AIDS Relief (PEPFAR) and other governmental and
non-governmental programmes. Women and children in the
study were screened for ART eligibility and treated according
to Tanzanian Ministry of Health guidelines. Based on the
previous findings on the beneficial effects of vitamin B
complex, C and E for pregnancy outcomes and to slow HIV
disease progression [12], all women received multivitamin
supplementation (vitamin B complex, C and E) during and
after pregnancy.
Laboratory measurement
Maternal HIV-1 serostatus was determined by two sequential
enzyme-linked immunosorbent assay (ELISA) using Murex
HIV antigen/antibody (Abbott Murex, UK) followed by
the Enzygnost anti-HIV-1/2 Plus (Dade Behring, Marburg,
Germany); discordant results were resolved by a Western blot
test (Bio-Rad Laboratories, Hertfordshire, UK). All children
were tested for HIV infection at baseline using the Amplicor
HIV-1 DNA assay version 1.5 (Roche Molecular Systems,
Inc., Branchburg, NJ, USA) and then again at 18 months using
HIV ELISAs. Samples from children who tested positive at
18 months were then backtested using the Amplicor HIV-1
DNA assay version 1.5 to estimate the time of transmission.
Children who were HIV-negative at 18 months and still
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from the study after 24 months of follow-up.
Blood specimens were requested from each mother at
baseline to measure complete blood counts including
haemoglobin concentrations and T-cell subset counts. Com-
plete blood counts, haemoglobin concentrations, and T-cell
subset counts were also measured for children at baseline
and every six months thereafter, until the end of the follow-
up. Haemoglobin concentrations were measured using AcT5
Diff AL haematology analyzer (Beckman Coulter, Jersey City,
NJ, USA) and T-cell subset, for example absolute CD4cell
count and percentage were performed with the FACSCalibur
system (Becton-Dickinson, San Jose, CA, USA).
Data management and analysis
The primary outcomes of the randomized controlled trial
were mortality and morbidity, and the main results have
been reported [13]. Assuming a mortality rate of 12.5% in the
placebo group, we planned to enrol 2360 infants to detect a
30% reduction in mortality in the treatment group with 80%
power at a significant level of 0.05 [13]. Assuming haemo-
globin concentrations are measured every six months, the
Figure 1. Sample sizes for analyses of haemoglobin (HB), anaemia (HBB11 g/dL), and severe anaemia (HBB8.5 g/dL).
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of 0.06 g/dL between the treatment and placebo groups
after 24 months of follow-up. Assuming 10% infants are HIV-
positive at baseline, the data provided 80% power to detect a
maximum relative risk of 0.6 for MTCT of HIV during the
follow-up period. Data were double-entered and validated
using Microsoft Access software. The final data sets were
converted into SAS software and uploaded to a UNIX-based
server in Boston, MA.
In this article, we aimed to analyze the secondary
outcomes including MTCT of HIV, child haemoglobin concen-
trations, and development of anaemia. Logistic regression
model was used to examine the association between multi-
vitamin supplementation and the risk of MTCT through
breastfeeding. Children who tested HIV-negative at baseline
and who had HIV testing during follow-up were included
in the analysis for MTCT (n1753). t-Tests were used to
evaluate the effect of multivitamin supplements on haemo-
globin concentrations. Cox proportional hazard models were
used to examine the effect of the multivitamin supplements
on the risk of development of anaemia and severe anaemia
during follow-up. Children with haemoglobin measured at
baseline and at least one follow-up haemoglobin measure
were included in the analysis for haemoglobin concentrations
(n2008) (Figure 1). We further excluded children who had
anaemia or severe anaemia at baseline from the respective
analyses conducted to determine the risk of developing
anaemia and severe anaemia during the follow-up period.
Baseline measures were those obtained within six weeks
after randomization. Anaemia was defined as haemoglobin
levelsB10.0 g/dL at baseline (six weeks of age) andB11
g/dL during follow-up, and severe anaemia was defined as
haemoglobinB8.5 g/dL [18]. We classified anaemia as
microcytic, normocytic, or macrocytic using mean corpuscu-
lar volume (MCV). The normal range of MCV was defined as
7086 fL for children at the age of 624 months [18]. In the
multivariate analyses, we considered potential confounders
and independent risk factors for anaemia from a list of
Table 1. Maternal and child baseline characteristics
Placebo Multivitamin
(N1006) (N1002)
Maternal characteristic
Age (y) 28.495.0
a 28.395.0
Education (%)
B8 y 80 78
]8 y 20 22
Employment (%)
Housewife without income 65 68
Housewife with income 16 13
Others 19 19
Possessions (%)
Have a sofa 74 72
Have a television 41 41
Have a radio 79 79
Have a refrigerator 24 25
Daily food expenditure per person (%)
5500 T Shillings
b 50 54
 500 T Shillings 50 46
Marital status (%)
Single 13 13
Married/living with partner 87 87
Prior pregnancies (%)
02 2 2 2
137 0 7 0
 38 8
Gestational age at enrolment (wk) 24.595.6 24.195.5
Body mass index (%)
B18.5 kg/m
2 44
18.5 B25 kg/m
2 55 57
25.0 B30 kg/m
2 31 30
]30 kg/m
2 10 9
Haemoglobin (%)
B11 g/dL 30 30
]11 g/dL 70 70
CD4 count, cells/mm
3 (%)
B200 cells/mm
3 99
200 B350 cells/mm
3 18 22
] 350 cells/mm
3 73 68
WHO disease stage (%)
I/II 87 89
III/IV 13 11
On anti-retroviral therapy during
pregnancy (%)
20 21
Child characteristics
Male (%) 53 54
Birth weight (kg) 3.190.5 3.190.5
Low birth weight B2.5 kg (%) 6 6
Prematurity, B37 weeks, (%) 15 14
Weight at baseline (kg) 4.590.7 4.590.7
Length/height-for-age z-score at baseline 0.4 (1.3) 0.3 (1.3)
Table 1 (Continued)
Placebo Multivitamin
(N1006) (N1002)
Weight-for-length/height z-score at
baseline
0.2 (1.3) 0.1 (1.2)
Weight-for-age z-score at baseline 0.5 (1.1) 0.4 (1.1)
Haemoglobin at baseline (g/dL) 10.4 (1.6) 10.4 (1.5)
HaemoglobinB10 g/dL (%) 42 40
HIV positive at baseline (%) 9 9
Received ART during study period (%) 5 5
CD4 percentage at baseline 37.3 (10.4) 37.5 (11.1)
Duration of exclusive breastfeeding
(months)
3.5 (2.1) 3.7 (2.1)
aMean9standard deviation (all such values).
b1250 T Shillings:1 USD.
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 28 years), CD4 counts (B200, 200B350, ]350 cells/
mm
3), WHO HIV disease stage (I/II, III/IV), antiretroviral
therapy during pregnancy (yes/no), sex of child (male/
female), birth weight (B2.5 kg, ]2.5 kg), preterm birth
(B37, ]37 weeks), HIV status (negative/positive), were
adjusted for in the models. Likelihood ratio tests were used
to test the interaction between multivitamin supplements
and potential effect modifiers.
All analyses were performed using the SAS software
Version 9.1 (SAS Institute, Cary, NC, USA). The significance
tests were two-sided and a p-value less than 0.05 was
considered statistically significant.
Ethics
The Harvard School of Public Health Human Subjects
Committee, and the Muhimbili University of Health and
Allied Sciences Research and Publications Committee granted
institutional review board approval. Written informed con-
sent was obtained from women for HIV testing and their
infant’s participation in the trial. The trial was registered at
clinicaltrials.gov (identifier NCT00197730).
Results
From August 2004 until November 2007, a total of 2387
infants were randomized into placebo or multivitamin treat-
ment groups. The two groups were comparable with respect
to mother’s age, education, economic status, gestational age
at enrolment, CD4 cell counts, ART during pregnancy and
infant sex, birth weight, baseline weight, HIV status and
CD4 cell percentage (Table 1). Infant exclusive breastfeed-
ing practices were not significantly different between the
treatment and placebo groups. Median (25th, 75th%) regi-
men compliance among children was 96 (91, 99)% of the
allocated regimen.
New cases of HIV infection during follow-up were identi-
fied in 34/880 (3.9%) children in the placebo group and
41/873 (4.7%) in the multivitamin treatment group. There
was no effect of multivitamin supplements on MTCT (odds
ratio1.23, 95% CI: 0.771.95, p0.39). There was also
no evidence of a differential effect of the supplements
when testing for interactions by baseline maternal CD4 cell
counts, haemoglobin levels or sex of the child.
Haemoglobin concentrations were similar between the
placebo and multivitamin treatment groups at baseline.
Haemoglobin concentrations, however, were significantly
higher in the treatment group at 12 months (mean 9.77 vs.
9.64 g/dL, p0.03), 18 months (9.76 vs. 9.57 g/dL, p0.004)
and 24 months (9.93 vs. 9.75 g/dL, p0.02) (Table 2). We
also conducted stratified analysis by baseline HIV status, sex
of the child and maternal haemoglobin levels, and found
that the beneficial effect of multivitamin supplement on
haemoglobin concentrations was statistically significant in
HIV-negative children and girls. We did not find significant
results among HIV-positive children and children born to
mothers with anaemia possibly due to the small sample in
these sub-groups. Tests for interaction by baseline HIV status
(p for interaction0.08), sex of the children (p for inter-
action0.07), and maternal haemoglobin levels (p for
interaction0.80) were not statistically significant.
We examined the efficacy of multivitamin supplementa-
tion on the risk of anaemia and severe anaemia. Eight
hundred and twenty four children (41%) with anaemia and
173 children (9%) with severe anaemia at baseline were
excluded from the respective analyses to determine risk for
anaemia and severe anaemia. During the follow-up, 1136
(96%) of the 1184 children and 458 (25%) of the 1835
children developed anaemia and severe anaemia, respec-
tively. Compared with children in the placebo group, children
in the treatment group had a 12% lower risk of developing
anaemia (HR: 0.88, 95% CI: 0.790.99, p0.03) and a 21%
lower risk of developing severe anaemia (HR: 0.79, 95% CI:
0.650.95, p0.01) after adjusting for potential confoun-
ders. Compared to children in the placebo group, children in
the treatment group had a 17% reduced risk of developing
normocytic anaemia and a 24% reduced risk of developing
severe microcytic anaemia (HR: 0.76, 95% CI: 0.610.93,
p0.009) (Table 3).
In the stratified analysis, we found that the effect of the
supplements on severe anaemia was only observed among
children born to women with haemoglobin concentrations
]11g/dL at baseline (HR: 0.72, 95% CI: 0.560.92, p0.008),
not among children born to women with anaemia, defined
as haemoglobin concentrationsB11g/dL (HR: 1.10, 95% CI:
0.791.54 p0.57; p for interaction0.007) (Table 4). The
protective effect of multivitamin supplements on anaemia
and severe anaemia was not modified by birth weight,
baseline HIV status, sex of child and maternal CD4cell
counts.
Discussion
In this randomized, placebo-controlled clinical trial, we found
that multivitamin supplementation (vitamin B complex, C
and E) was significantly associated with increased haemoglo-
bin concentrations and a decreased risk of anaemia among
children born to HIV-positive mothers. In addition, among
children born to mothers with haemoglobin concentrations
]11g/dL, supplementation was associated with a reduced
risk of severe anaemia, but not among children born to
mothers with anaemia. The associations between multi-
vitamin supplementation with haemoglobin levels and
anaemia status were not significantly different between
boys and girls. To our knowledge, this is the first trial in
which multivitamin supplements were given to HIV-exposed
infants as early as six weeks of age. The findings are
consistent with a previous study in which a similar mix of
multivitamins (vitamin B complex, C and E) was provided to
HIV-positive women during pregnancy and in the postpartum
period. The study showed that multivitamin supplementa-
tion significantly improved the haematologic status of both
the mother and the child [4]. However, Chhagan et al. [10]
recently examined the effect of multiple micronutrients
on anaemia among a representative sample of HIV-negative
children born to HIV-negative women, HIV-negative children
born to HIV-positive women, and HIV-positive children in
rural South Africa. They did not find significant differences
between the treatment and control groups, perhaps due to
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5Table 2. Effects of multivitamin supplement on haemoglobin concentrations
Placebo Multivitamin P
a
Overall
n 1006
b 1002
Baseline 10.36 (1.65)
c 10.35 (1.47) 0.92
6 mo 9.72 (1.02) 9.71 (1.08) 0.76
12 mo 9.64 (1.23) 9.77 (1.17) 0.03
18 mo 9.57 (1.38) 9.76 (1.21) 0.004
24 mo 9.75 (1.31) 9.93 (1.35) 0.02
HIV-negative at baseline
n 911 909
Baseline 10.37 (1.66) 10.37 (1.48) 0.98
6 mo 9.78 (0.99) 9.78 (1.05) 0.96
12 mo 9.69 (1.22) 9.80 (1.14) 0.06
18 mo 9.61 (1.32) 9.80 (1.21) 0.008
24 mo 9.76 (1.32) 9.98 (1.33) 0.008
HIV positive at baseline
n 88 85
Baseline 10.39 (1.56) 10.18 (1.42) 0.35
6 mo 9.15 (1.18) 8.89 (1.08) 0.14
12 mo 9.20 (1.26) 9.35 (1.48) 0.55
18 mo 9.12 (1.97) 9.22 (1.17) 0.75
24 mo 9.62 (1.15) 9.28 (1.43) 0.26
Maternal haemoglobin concentrations ]11 g/dL at baseline
n 629 627
Baseline 10.41 (1.65) 10.43 (1.46) 0.84
6 mo 9.76 (1.02) 9.83 (1.07) 0.27
12 mo 9.72 (1.21) 9.84 (1.17) 0.11
18 mo 9.66 (1.45) 9.81 (1.24) 0.10
24 mo 9.82 (1.25) 10.00 (1.42) 0.07
Maternal haemoglobin concentrations B11 g/dL at baseline
n 272 261
Baseline 10.24 (1.65) 10.23 (1.54) 0.92
6 mo 9.62 (1.01) 9.43 (1.12) 0.04
12 mo 9.46 (1.19) 9.61 (1.19) 0.20
18 mo 9.43 (1.26) 9.63 (1.20) 0.11
24 mo 9.56 (1.39) 9.76 (1.28) 0.21
Boys
n 530 546
Baseline 10.19 (1.49) 10.24 (1.40) 0.56
6 mo 9.64 (1.02) 9.64 (1.03) 0.96
12 mo 9.55 (1.29) 9.70 (1.20) 0.07
18 mo 9.50 (1.35) 9.63 (1.20) 0.16
24 mo 9.74 (1.31) 9.80 (1.31) 0.64
Girls
n 476 456
Baseline 10.55 (1.79) 10.49 (1.40) 0.54
6 mo 9.81 (1.02) 9.79 (1.13) 0.78
12 mo 9.74 (1.16) 9.85 (1.12) 0.15
18 mo 9.64 (1.41) 9.92 (1.22) 0.006
24 mo 9.74 (1.31) 10.08 (1.38) 0.004
ap-Value based on t-test comparing multivitamin versus placebo group.
bn is the number of children included in the analysis.
cMean (standard deviation), all such values.
Liu E et al. Journal of the International AIDS Society 2013, 16:18022
http://www.jiasociety.org/index.php/jias/article/view/18022 | http://dx.doi.org/10.7448/IAS.16.1.18022
6the small sample size, high prevalence of anaemia at baseline
and lower dose of the micronutrient supplements.
There are several plausible mechanisms by which vitamins
included in the supplementation might have improved
haemoglobin levels. First, vitamin C enhances the absorption
of iron in the intestine [19]. Second, as an antioxidant, vitamin
E inhibits the oxidative damage of erythrocyte membrane
by free radicals, and this function is also performed and
enhanced by vitamin C [20,21]. Third, B vitamins, especially
riboflavin (B2) and vitamin B6, play a role in the synthesis of
haemoglobin, thereby enhancing erythropoiesis [22].
We found that multivitamin supplements reduced the risk
of severe anaemia among children born to mothers with
haemoglobin concentrations ]11 g/dL, but not among
children born to mothers with anaemia (p for interaction
0.007). In this study, children born to anaemic mothers had
lower haemoglobin concentrations than those born to
mothers without anaemia. Several longitudinal studies have
Table 3. Effects of multivitamin supplementation on risk of anaemia and severe anaemia
a
Outcomes Placebo Multivitamins p
Anaemia (haemoglobin B11 g/dL)
n
b 585 599
Person-months 3428 3694
Number of cases 566 570
HR (95% CI)
c 1.00 0.88 (0.790.99) 0.04
HR (95% CI)
d 1.00 0.88 (0.780.99) 0.03
Anaemiamicrocytosis (haemoglobin B11 g/dL and MCV B70 fL)
No. of Cases 261 287
HR (95% CI)
c 1.00 0.95 (0.811.13) 0.58
HR (95% CI)
d 1.00 0.94 (0.801.12) 0.50
Anaemianormocytosis (haemoglobin B11 g/dL and 70 5MCV B86 fL)
Number of cases 295 280
HR (95% CI)
c 1.00 0.84 (0.710.99) 0.04
HR (95% CI)
d 1.00 0.83 (0.700.98) 0.03
Anaemiamacrocytosis (haemoglobin B11 g/dL and 70 5MCV B86 fL)
Number of cases 9 3
HR (95%CI)
c 1.00 0.29 (0.081.09) 0.07
HR (95%CI)
d 1.00 
Severe anaemia (haemoglobin B8.5 g/dL)
n
e 916 919
Person-months 13,653 14,063
Number of cases 253 205
HR (95% CI)
c 1.00 0.78 (0.650.93) 0.007
HR (95% CI)
d 1.00 0.79 (0.650.95) 0.01
Severe anaemiamicrocytosis (haemoglobin B8.5 g/dL and MCV B70 fL)
Number of cases 203 159
HR (95% CI)
c 1.00 0.75 (0.610.92) 0.007
HR (95% CI)
d 1.00 0.76 (0.610.93) 0.009
Severe anaemianormocytosis (haemoglobin B8.5g/dL and 70 5MCV B86 fL)
Number of cases 45 44
HR (95% CI)
c 1.00 0.94 (0.621.42) 0.75
HR (95% CI)
d 1.00 0.94 (0.621.43) 0.77
Anaemiamacrocytosis (haemoglobin B11 g/dL and 70 5MCV B86 fL)
Number of cases 3 2
HR (95% CI)
c 1.00 0.63 (0.113.78) 0.61
HR (95% CI)
d 1.00 
aHazard ratio (HR) and 95% CI were estimated from Cox regression for the contrast of the multivitamins treatment to placebo.
bn is the number of children without anaemia at baseline, included in the analysis of anaemia.
cUnivariate analysis.
dAdjusted for maternal age (528,  28 years), haemoglobin level (B11 g/dL, ] 11g/dL), CD4 counts (B200, 200B350, ]350 cells/
mm
3), WHO HIV disease stage (I/II, III/IV), antiretroviral therapy during pregnancy (yes/no), sex of child (male/female), birth weight (B2.5 kg,
]2.5 kg), preterm birth (B37, ]37 weeks), HIV status (negative/positive).
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7also shown that maternal haemoglobin or iron status during
pregnancy is associated positively with infant body iron at
birth, and a significant predictor for incidence of anaemia
during infancy [2325]. In addition, women with lower
haemoglobin concentrations are likely to have a diet with
low iron content and feed their children with a similar diet
to theirs.The low body iron store at birth and low iron intake
among children born to women with anaemia might explain
the difference in effect of multivitamin supplements on the
risk of severe anaemia. Due to the small sample size for
infants born to a mother with anaemia, we may have lacked
the power to detect any protective effect of the multi-
vitamin supplements in this subgroup, thereby were not
able to assess the difference in the effect of multivitamin
supplements between infants born to mothers with anaemia
versus without anaemia.
A few randomized controlled trials have demonstrated that
direct supplementation of multiple micronutrients is asso-
ciated with increased haematologic status among young
children [7,10]. The International Research on Infant Sup-
plementation Study, in which the supplements were given
to infants as chewable tablets (or foodlets), have consis-
tentlyshownthatsupplementationofmultiplemicronutrients
improved anaemia status among infants aged 612 months in
developing countries, including Indonesia, Peru, South Africa,
and Vietnam [2629]. Zlotkin and colleagues [9,30,31] found
that the micronutrient Sprinkles, is effective in improving
haemoglobin status and reducing the anaemia prevalence
among young children. Iron was included in the treatment
regimens in these trials [9,2631]. We did not provide iron
in this study; however, children in the multivitamin treat-
ment group still had higher haemoglobin concentrations
and a lower risk of anaemia than those in the placebo group.
We did not include iron in our regimen because there are
concerns over a possible deleterious effect of iron supple-
mentation among non-anaemic and/or HIV-positive children.
Iron is capable of inducing oxidative stress, as well as serving
as an essential nutrient for microbial pathogens [32].
Some but not all observational studies have shown that
high iron stores in HIV-positive individuals were associated
with shorter survival time and higher mortality [3335].
A large community-based, randomized, placebo-controlled
trial in Pemba, Zanzibar demonstrated an increased risk of
serious morbidity among children under the age of three
years who were given routine daily iron supplements [32].
The prevalence of anaemia at the study baseline is 57%,
and according to the data from the National survey 1.1% of
the population in Zanzibar is HIV-positive [36]. Randomized
clinical trials to assess the effect of iron supplements on
morbidity and mortality among HIV-positive children are
lacking [37].
Anaemia is an important public health problem among
young children in resource-limited setting. Studies have
repeatedly demonstrated that children with lower concentra-
tions of haemoglobin have a high risk of mortality and
morbidity [3840]. While the observed effect of increasing
haemoglobin by 0.2 g/dL appears modest at the level of
an individual child, shifting the population distribution of
Table 4. Hazard ratio (HR) of severe anaemia (haemoglobin B8.5 g/dL) associated with multivitamin supplements by baseline
maternal haemoglobin levels
a
Maternal haemoglobin
concentrations at baseline Placebo Treatment p
b p
c
B11 g/dL N 244 238 0.007
Person-months 3651 3360
Number of cases 70 73
HR (95% CI)
d 1.00 1.10 (0.791.54) 0.57
]11 g/dL N 575 576
Person-months 8712 9122
Number of cases 158 117
HR (95% CI)
d 1.00 0.72 (0.560.92) 0.008
Boys N 473 491
Person-months 6892 7312
Number of cases 144 118
HR (95% CI)
d 1.00 0.77 (0.600.99) 0.04 0.82
Girls N 443 428
Person-months 6761 6751
Number of cases 109 87
HR (95% CI)
d 1.00 0.79 (0.591.06) 0.11
aHR and 95% CI were estimated from Cox regression for the contrast of the multivitamins treatment to placebo.
bp-Value estimated from Cox regression to compare the multivitamins group with placebo group.
cp-Value for the interaction between multivitamin supplementation and maternal haemoglobin concentrations.
dAdjusted for maternal age (528,  28 years), CD4 counts (B200, 200B350, ]350 cells/mm
3), WHO HIV disease stage (I/II, III/IV),
antiretroviral therapy during pregnancy (yes/no), sex of child (male/female), birth weight (B2.5 kg, ]2.5 kg), preterm birth (B37, ]37
weeks), HIV status (negative/positive).
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8haemoglobin by this much is likely to have a significant effect
on child health and survival. All mothers in this trial were
provided high-dose micronutrient supplements throughout
the study period. Maternal micronutrient supplementation
may positively impact quality of life among pregnant HIV-
positive women and improve their breast milk nutrient
quantity [41], thereby indirectly increasing infant micronu-
trient intake. It is possible that in areas of the world where
maternal micronutrient supplementation is not a standard
of care, direct infant micronutrient supplementation could
result in even greater improvements in the haemoglobin
status of children born to HIV-positive mothers.
We did not find any association between multivitamin
supplements and risk of MTCT of HIV through breastfeeding.
The result did not change in analysis stratified by sex of the
child. To our knowledge, this is the first randomized study to
examine whether direct multivitamin supplements adminis-
tered to infants reduce MTCT of HIV. One previous study has
found that maternal multivitamin supplementation (vitamin
B complex, C and E) decreased the risk of MTCTof HIVamong
immunologically and nutritionally compromised HIV-positive
women [11]. In this study, the provision of multivitamin
supplementation to all women during the study period may
have, in part, explained the null effect of direct multivitamin
supplements to infants born to these women on MTCT of
HIV.
Several limitations of the study should be noted. First,
the haemoglobin and anaemia status of infants and mothers
were not the primary outcomes of this randomized controlled
trial, and 16% of infants without haemoglobin measures at
baseline or during follow-up were not included in the analysis.
Therefore, the beneficial effect of multivitamin supplemen-
tation on haemoglobin concentrations needs further exam-
ination in a large trial that focuses on haemoglobin and
anaemia status in the target population. Second, in the
current trial, only 20% of HIV-positive women initiated ART
during pregnancy. Given the increased access to ART among
HIV-positive pregnant and lactating women in resource-
limited settings during the past five years, our results have
to be considered carefully before being applied to other HIV-
exposed child populations in the current ART era. Antiretro-
viral drugs, such as zidovudine and most other nucleoside
reverse transcriptase inhibitors, easily cross the placenta
and suppress erythroid progenitor cells [42]. A few studies
have indicated that antenatal exposure to ART is associated
with an increased risk of haematologic abnormalities among
infants during the first three months of life [2,43].
Conclusion
In a randomized clinical trial, we found that multivitamin
supplementation to children born to HIV-positive mothers
was associated with better haematological status but not a
reduction of MTCT of HIV. As iron deficiency anaemia is
the most common type of anaemia among HIV-exposed or
HIV-positive children, there is an urgent need for randomized
control trials to examine the efficacy and safety of multi-
vitamin supplements with iron included in the context of HIV
infection and ART.
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